Evidence map›Paper›PMID 25889517›Full record

ArticleBMC research notes2015

Fastq2vcf: a concise and transparent pipeline for whole-exome sequencing data analyses.

Xiaoyi Gao, Jianpeng Xu, Joshua Starmer

Abstract read
In one paragraph

Article in BMC research notes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Resources and tools for rare disease variant interpretation.Frontiers in molecular biosciences · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaoyi GaoDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, 60612, USA. rgao@uic.edu.
Jianpeng XuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, 60612, USA. jxu006@gmail.com.
Joshua StarmerDepartment of Genetics, University of North Carolina-Chapel Hill, Chapel Hill, NC, 27599, USA. josh.starmer@gmail.com.

Funding

Mexican American Glaucoma Genetic Study (MAGGS)R01EY022651 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GAO, XIAOYI RAYMOND · 2012 to 2016
$4.2M
NEI NIH HHS R01 EY022651NEI NIH HHS R01EY022651
6 · The paper itself

Abstract

backgroundWhole-exome sequencing (WES) is a popular next-generation sequencing technology used by numerous laboratories with various levels of statistical and analytical expertise. Centralized databases, such as the Sequence Read Archive and the European Nucleotide Archive, allow data to be reanalyzed by independent labs to confirm results and derive additional insights. Access to new and shared data highlights the necessity for software that both lowers the statistical and analytical expertise required to generate results and promotes reproducible methodology among laboratories.

findingsWe have developed fastq2vcf, a pipeline that automates the genomic variant calling process using multiple callers. Fastq2vcf offers improved flexibility, efficiency, and reproducibility by seamlessly integrating several leading sequencing analysis tools. It outputs not only the annotated variant call set for each caller, but also the consensus variant call set shared by different callers. Furthermore, it can be customized and extended easily.

conclusionsOur software tool automatically generates executable command lines for a variety of tools required for analyzing WES data. It is also highly configurable and provides users with complete control of the processing procedure, making it easy to submit and track jobs in both single workstation and parallelized computing environments. By using this pipeline, WES analysis can be easily reproduced.

Indexed as

ExomeSoftwareBenchmarkingHigh-Throughput Nucleotide SequencingHumansQuality ControlReproducibility of Results

Identifiers

PMID25889517
PMCPMC4376134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.